These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17668165

  • 1. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ, Hegele A, Olbert P, Buer J, Jeron A, Hofmann R.
    Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
    [No Abstract] [Full Text] [Related]

  • 2. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M, Ishida-Yamamoto A, Komatsu S, Iiduka H.
    J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
    [No Abstract] [Full Text] [Related]

  • 3. Hand-foot and stump syndrome to sorafenib.
    Lai SE, Kuzel T, Lacouture ME.
    J Clin Oncol; 2007 Jan 20; 25(3):341-3. PubMed ID: 17235051
    [No Abstract] [Full Text] [Related]

  • 4. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC, Easson AM, Szentgyorgyi E, Knox JJ.
    Eur J Surg Oncol; 2009 Feb 20; 35(2):219-21. PubMed ID: 17976949
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
    Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue TA, Fujisawa M.
    BJU Int; 2010 Dec 20; 106(11):1643-7. PubMed ID: 20553261
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.
    J Clin Oncol; 2009 Jul 10; 27(20):3312-8. PubMed ID: 19451442
    [Abstract] [Full Text] [Related]

  • 16. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
    Kennoki T, Kondo T, Kimata N, Murakami J, Ishimori I, Nakazawa H, Hashimoto Y, Kobayashi H, Iizuka J, Takagi T, Yoshida K, Tanabe K.
    Jpn J Clin Oncol; 2011 May 10; 41(5):647-55. PubMed ID: 21367805
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
    Takeuchi A, Eto M, Tatsugami K, Yamada H, Oki T, Kiyoshima K, Yoshikai Y, Naito S.
    J Urol; 2010 Dec 10; 184(6):2549-56. PubMed ID: 21030044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.